Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Dec 9, 2014; 3(4): 186-192
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.186
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.186
Use of eltrombopag in thrombocytopenia of liver disease
Vishal Sharma, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh 160011, India
Author contributions: Sharma V solely contributed to this paper.
Correspondence to: Vishal Sharma, Assistant Professor, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160011, India. docvishalsharma@gmail.com
Telephone: +91-950-1013399
Received: May 16, 2014
Revised: July 4, 2014
Accepted: September 17, 2014
Published online: December 9, 2014
Processing time: 210 Days and 8.8 Hours
Revised: July 4, 2014
Accepted: September 17, 2014
Published online: December 9, 2014
Processing time: 210 Days and 8.8 Hours
Core Tip
Core tip: Thrombocytopenia associated with liver disease is multifactorial. Eltrombopag, a thrombopoietin agonist, has been found useful in increasing platelet counts in these patients. It has been clinically used to increase platelet counts in cirrhotic patients prior to invasive procedures and in patients with chronic hepatitis C to enable administration of interferon based antiviral therapy. However, there are concerns regarding its safety and possible increased risk of portal vein thrombosis.